Phase 1
N=3
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
BRAF V600E Unresectable or Metastatic Melanoma · BRAF V600E Metastatic NSCLC · Melanoma
Bottom Line
View on ClinicalTrials.gov: NCT05003622 ↗Enrolled (actual)
3
Serious AEs
66.7%
Results posted
Jun 2024
Primary outcome: Primary: Dose Limiting Toxicities (DLTs) Experienced During Cycle 1 — 0 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- Encorafenib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pierre Fabre Medicament
- Primary completion
- May 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose Limiting Toxicities (DLTs) Experienced During Cycle 1 |
— | — |
| SECONDARY Occurrence of Treatment Emergent Adverse Events (TEAEs) |
53; 17; 3; 2; 3; 2 | — |
| SECONDARY Notable Change From Baseline of Blood Hematology Parameters: Hemoglobin, Leukocytes, Neutrophils, Platelets, Lymphocytes. |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Notable Change From Baseline of Blood Clinical Chemistry Parameters |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Notable Change From Baseline of Coagulation Parameters |
3; 0; 0; 0; 0; 2 | — |
| SECONDARY Notable Change From Baseline of Dipstick Urinalysis |
3; 0; 3; 0; 3; 0 | — |
| SECONDARY Notable or Abnormal Changes in Vital Signs From Baseline of Vital Sign Examinations. |
1; 1; 1; 0; 0; 0 | — |
| SECONDARY Notable or Abnormal Changes From Baseline of 12-lead Electrocardiograms (ECGs) |
1; 0; 0; 0; 0; 1 | — |
| SECONDARY Occurrence of Targeted Treatment Emergent Adverse Events (TEAEs) of Special Interest |
— | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib: Area Under the Curve (AUC) After Single and Repeated Administration of Encorafenib |
21800; 9550 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): Area Under the Curve (AUC) After Single and Repeated Administration of Encorafenib Metabolite (LHY746) |
2540; 6020 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib: Maximum Concentration (Cmax) After Single and Repeated Administration of Encorafenib |
5590; 3630 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): Maximum Concentration (Cmax) After Single and Repeated Administration of Encorafenib |
610; 1420 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib: Minimum Concentration (Cmin) After Single and Repeated Administration of Encorafenib |
NA; 10.5 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): Minimum Concentration (Cmin) After Single and Repeated Administration of Encorafenib |
NA; 109 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib: Time Taken to Reach Maximum Concentration (Tmax) After Single and Repeated Administration of Encorafenib |
2.00; 1.00 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): Time Taken to Reach Maximum Concentration (Tmax) After Single and Repeated Administration of Encorafenib Metabolite (LHY746) |
5.98; 2.00 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib: ARAUC After Single and Repeated Administration of Encorafenib |
0.440 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): ARAUC After Single and Repeated Administration of Encorafenib Metabolite (LHY746) |
2.27 | — |
| SECONDARY Plasma Pharmacokinetics (PK) of Encorafenib Metabolite (LHY746): MRAUC After Single and Repeated Administration of Encorafenib Metabolite (LHY746) |
0.141; 0.730 | — |
Summary
This is a phase 1, multicenter, open-label, single-arm study to investigate the safety and tolerability of encorafenib 300 mg once daily (QD) monotherapy in adult Chinese participants with B-RAF Proto-oncogene, Serine/threonine Kinase V600E (BRAF V600E) mutant advanced solid tumors (unresectable metastatic melanoma or metastatic non-small cell lung cancer (NSCLC)), who are BRAF-inhibitor treatment-naïve and have failed the previous therapy(ies) in the metastatic setting or are not eligible to standard therapy. Participants will be eligible for the study based on identification of a BRAF V600E mutation in tumor tissue by a local National Medical Products Administration (NMPA) approved assay obtained prior to screening.
Eligibility Criteria
Inclusion Criteria
- Provide a signed and dated informed consent form (ICF).
- Chinese male or female with age ≥18 years old at the time of the informed consent.
- Documented histology- and/or cytology-confirmed metastatic melanoma or non-small cell lung cancer (NSCLC) (i.e. adenocarcinoma, large cell carcinoma, squamous cell carcinoma).
- Presence of B-RAF Proto-oncogene, Serine/threonine Kinase V600E Mutant (BRAF V600E) mutation as determined by a local laboratory with a National Medical Products Administration (NMPA) approved BRAF test.
- BRAF inhibitor treatment-naïve participants and having failed the previous therapy(ies) for metastatic disease or are not eligible to standard therapy.
- At least one tumor lesion as per investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, which has neither been irradiated nor biopsied during the screening period. The irradiated lesion is acceptable only if it is proven as disease progression deemed measurable prior to study.
- Life expectancy ≥3 months.
- Eastern Co-operative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate hematologic function at screening and baseline
- Adequate hepatic function at screening and baseline
- Adequate renal function at screening and baseline
- Able to comply with the study protocol as per investigator assessment including oral drug intake, complying scheduled visits, treatment plan, laboratory tests and other study procedures.
- Women are either postmenopausal for at least 1 year, or are surgically sterile for at least 6 weeks, or women of childbearing potential (WOCBP) must agree to take appropriate precautions to avoid pregnancy.
- Men must agree not to father child until 90 days after the last dose of study treatment.
Exclusion Criteria
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to encorafenib, or its excipients.
- For metastatic NSCLC: documented anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 (c-ros oncogene 1) rearrangement or epidermal growth factor receptor (EGFR) sensitizing or driver mutation.
- Receipt of anticancer medications or investigational drugs within intervals before the first administration of study treatment.
- Symptomatic brain metastasis.
- Leptomeningeal disease.
- Participant has not recovered to ≤Grade 1 from toxic effects of prior therapy and/or complications from prior surgical treatment before starting study treatment.
- Current use of prohibited medication ≤1 week prior to start of the study treatment and/or concomitantly.
- Impairment of gastrointestinal function or disease which may significantly alter the absorption of oral study treatment.
- Impaired cardiovascular function or clinically significant cardiovascular diseases.
- Participants with active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) or any other severe viral active infection (e.g. severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection).
- Evidence of active, non-infectious pneumonitis, history of interstitial lung disease that required oral or intravenous glucocorticoid steroids for management.
- Known history of a positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). Testing for HIV must be performed at sites where mandated locally.
- Participants who have had major surgery (e.g. inpatient procedure with regional or general anesthesia) within 6 weeks prior to start of study treatment.
- Previous or concurrent malignancy within 2 years of study entry.
Except:
- Bowen's disease.
- Cured basal cell or squamous cell skin cancer.
- Gleason 6 prostate cancer.
- Treated in-situ carcinoma of cervix.
- Participant's conditions that contraindicates the use of study treatment and may affect interpretation of results or that may render the participant at high risk from treatment complications.
- Pregnant (confirmed by posi
Data sourced from ClinicalTrials.gov (NCT05003622). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.